Predicting Successful Phase Advancement and Regulatory Approval in Multiple Myeloma From Phase I Overall Response Rates

Drug development in oncology is resource intensive, time consuming, and frequently unsuccessful. Here, we hypothesized that therapeutic benefit of published phase I studies of antimyeloma investigational agents was associated with advancement to phase II and future regulatory approval. PATIENTS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Malek, Ehsan, Saygin, Caner, Ye, Rebecca, Covut, Fahrettin, Kim, Byung-Gyu, Welge, Jeffrey, Meropol, Neal J., De Lima, Marcos, Driscoll, James J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2017
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797233/
https://www.ncbi.nlm.nih.gov/pubmed/30657399
http://dx.doi.org/10.1200/CCI.17.00055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9797233/
https://www.ncbi.nlm.nih.gov/pubmed/30657399
http://dx.doi.org/10.1200/CCI.17.00055

Ejemplares similares